BACKGROUND: Soluble ST2 (sST2), an interleukin-1 receptor family member, is an emerging risk indicator for patients with cardiovascular disease. We evaluated the prognostic role of sST2 for patients presenting to the emergency department with acute dyspnea, with a focus on those with preserved left ventricular ejection fraction (LVEF Ն50%), as risk stratification is often most complex in this subgroup.
those with preserved LVEF, and may be useful for triage and risk stratification of this challenging group.
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ST2 is an interleukin-1 family receptor that is expressed in cardiomyocytes. The receptor has 2 isoforms: a transmembrane bound form and a soluble circulating form (sST2), 6 which lacks the intracellular and transmembrane domains. The ligand for both isoforms is interleukin (IL)-33, which, when bound to the transmembrane form of the receptor, exerts a potentially protective antihypertrophic, antifibrotic effect on the cardiomyocyte (1, 2 ) . The soluble unbound isoform binds and removes IL-33 from the circulation, thus potentially promoting adverse remodeling and fibrosis by blunting activation of the transmembrane receptor (3 ) .
Expression of sST2 may be related to a mechanoreceptor and stretch-related mechanism in the myocardium. sST2 has therefore been evaluated as a prognostic marker in cardiovascular disease (4 ) . Increased serum concentrations of sST2 occurring early after myocardial infarction are associated with increased risk of mortality and development of heart failure (HF) (5, 6 ) . In patients with chronic systolic HF, an increase in serum sST2 predicted death or heart transplantation (7 ) . Increased sST2 concentrations have demonstrated prognostic value additive to that of natriuretic peptides for patients who presented to the hospital with acute decompensated HF (ADHF) or acute dyspnea (8, 9 ) .
We investigated the prognostic role and the echocardiographic and clinical correlates of sST2 in patients presenting to the emergency department (ED) with acute dyspnea. We hypothesized that sST2 is a predic-tor of mortality in patients with acute dyspnea and preserved myocardial systolic function [left ventricular ejection fraction (LVEF) Ն50%].
Materials and Methods
This study is a post hoc analysis of a prospective, 5-center cohort study that was approved by institutional review boards of the participating study centers. The original study enrolled 412 patients from May 2003 through December 2006, with 5 sites added on a sequential basis to provide diversity to the demographics of recruited subjects. Analyses related to natriuretic peptides, myeloperoxidase, and echocardiographic parameters have been published (10 -12 ) .
We measured serum sST2 in blood samples from 387 patients in the present study. Patients were included if they were Ն18 years old and presented to an ED with a primary complaint of dyspnea. Exclusion criteria were exogenous causes of dyspnea (e.g., trauma, upper airway obstruction), pneumothorax, and acute coronary syndrome, defined as a clinical suspicion of cardiac ischemia or infarction accompanied by either ST-segment deviation Ն1 mm or serum troponin concentration above the upper reference limit for the local laboratory on enrollment. Written informed consent was obtained from all patients enrolled in the study.
An expert panel of physicians trained in cardiovascular medicine reviewed the presenting signs and symptoms, medical history, medications, echocardiography, and electrocardiograms to diagnose ADHF by use of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial criteria (13 ) . Structural heart disease was defined as LVEF Յ40% without a diagnosis of ADHF. Two panel members reviewed each case; if they disagreed, a third expert was consulted. The panel members were not directly involved in the care of the patients and were blinded to the results of the biomarkers and ED diagnosis. Twelvemonth follow-up status was determined using telephone interview, review of medical records, and search of the Social Security Death Index.
ECHOCARDIOGRAPHY
Echocardiography was offered to all subjects for purposes of this research protocol. Prospective echocardiography was performed within 96 h of enrollment on 316 of 387 (81%) patients. Echocardiograms were performed by an experienced sonographer, and the studies were sent to the core laboratory (University of Maryland) on videotape or digital media. A single investigator blinded from the clinical data analyzed the images to minimize interobserver variability. Determination of LVEF was technically feasible in 290 (92%) of the completed echocardiograms.
We used Simpson's biplane analysis to determine LV end systolic and end diastolic volume (LVESV and LVEDV) (10 ) . LVEF was calculated as [(LVEDV Ϫ LVESV)/LVEDV] ϫ 100%. Preserved LVEF was defined as LVEF Ն50%. We determined left ventricular mass, indexed for body surface area, by use of the M-mode criteria recommended by the American Society of Echocardiography and the formula proposed by Devereux et al. (14 ) .
We assessed diastolic function in the apical 4-chamber view. Doppler evaluations of early (E) and late (A) mitral inflow velocities and tissue Doppler imaging sampling from the lateral mitral annulus (Em) were obtained to grade the severity of diastolic dysfunction as stage I [impaired relaxation, E/A Ͻ1, and deceleration time (Dt) Ͼ 220 ms], II (pseudonormal, E/A between 1 and 2, Dt Ͻ220 ms, and Em Ͻ8.5 m/s), or III (restrictive, E/A Ͼ2, and Dt Ͻ150 ms) (15 ) . We determined the E/Em ratio, where a value of Ͻ8 predicts normal filling pressures and Ͼ15 predicts increased filling pressures (16 ) .
BIOCHEMISTRY
At the time of patient enrollment, 20 mL of blood was drawn (3 separate tubes containing EDTA, heparin, and no anticoagulant). Within 2 hours, blood samples were centrifuged and stored at Ϫ70°C or colder. The frozen samples were shipped on dry ice to the Core Laboratory at the University of Maryland and then maintained at Ϫ70°C until measurement, which was between 2 and 5 years later. We measured serum sST2 concentration by ELISA (Presage ST2 assay, Critical Diagnostics), with reference intervals for men and women being 3-28 U/mL and 2-16 U/mL, respectively (17 ) . Total imprecision observed for the ST2 assay for the study was Ͻ6% at 52.5 U/mL, similar to that published previously (17 ) . ST2 measurements in specimens demonstrated recovery of 99% to 101% after similar storage for 18 months (18 ) . Cardiac troponin I (cTnI) measurements were performed with the Stratus CS system (Siemens Diagnostics). Characteristics of this assay include detection limit 0.010 g/L, 10% CV limit 0.06 g/L, and 99th percentile of a reference population established as 0.07 g/L (19 ) .
We measured amino-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) with 1-step immunometric sandwich assays that use antibodies specific for the respective analytes; both NT-proBNP and hsCRP were measured on the Dimension RxL system [Dade Behring (now Siemens Healthcare Diagnostics)]. For hsCRP, total CVs were 5.7% at 0.53 mg/L, 2.1% at 2.42 mg/L, and 2.4% at 6.4 mg/L; for NT-proBNP, total imprecision was 9.3% at159 ng/L, 3.7% at 449.5 ng/L, and 3.6% at 956.7 ng/L. Myeloperoxidase (MPO), in EDTA-containing plasma collected into plastic tubes, was also measured by immunoassay on the Dimension RxL system (Siemens Healthcare Diagnostics). MPO measurements in plasma are stable for Ͼ1 year when stored at Ϫ20°C (Dr. Mary Lou Gantzer, personal communication, Siemens Healthcare Diagnostics, approximately April 2, 2010). For MPO, the total CV observed was 4.0% at 403 pmol/L and 2.0% at 3631 pmol/L. Individuals processing the blood were blinded from any patient data. We calculated the estimated glomerular filtration rate (eGFR) using the modified Modification of Diet in Renal Disease equation (20 ) .
STATISTICAL ANALYSIS
Continuous and categorical variables are presented as mean (SD) and percentage, respectively; biomarkers with nonnormal distributions are reported by the median concentration and interquartile range (IQR). We evaluated associations of the biomarker concentrations with clinical, biochemical, and echocardiographic measures using Spearman nonparametric correlation coefficients and linear regression modeling. Stepwise addition of all clinical and biochemical variables was performed in the linear regression modeling for multivariate assessment of predictors of sST2. We used 2 tests to compare proportions, Student t-tests and ANOVA to compare normally distributed continuous variables, and Mann-Whitney U and Kruskal-Wallis 
Results

PATIENT CHARACTERISTICS
Clinical characteristics of the 387 patients are presented in Table 1 . Sixty-five percent of patients were African American, 61% were men, and age was 57.6 (14.5) years. The median values (IQR) of sST2 and NTproBNP were 38.4 (25.5-64) U/mL and 315 (36.7-2836) ng/L, respectively. The diagnosis of ADHF was present in 34% of patients, and 12% of additional patients had evidence of structural heart disease in the absence of ADHF. On echocardiography, patients with LVEF Ն50% were younger and had higher eGFRs and lower sST2 and NT-proBNP concentrations. Concentrations of markers of inflammation, MPO and hsCRP, were similar in groups with preserved and depressed LVEF. Patients with an LVEF Ն50% were more likely to be female and black and less likely to have a history of coronary disease, hypertension, or diagnosis of acute heart failure as the cause of their dyspnea. Patients with lower LVEF were more likely to have received ACE inhibitors or angiotensin receptor blockers, ␤-blockers, digoxin, and diuretics, whereas those with preserved LVEF were more likely to have received bronchodilators (Table 1) .
Of the 100 patients with an ADHF diagnosis, 29 (29%) had LVEF Ն50%. Of those patients completing echocardiography with dyspnea without ADHF (190 patients), 171 (90%) had LVEF Ն50%. Of these patients, 8% had stage II or III diastolic dysfunction suggestive of increased left ventricular diastolic filling pressure.
ASSOCIATION BETWEEN sST2 CONCENTRATION AND SURVIVAL
Follow-up information at 1-year was complete for 376 of 387 (97%) patients, of whom 46 (12%) had died. Kaplan-Meier analysis revealed that survival decreased with each tertile of sST2 (first, 96%; second, 92%; third, 75%; log-rank P Ͻ 0.001) (Fig. 1) and NT-proBNP (first, 98%; second, 85%; third, 82%; log-rank P Ͻ 0.001). Both sST2 [hazard ratio (HR) (95% CI) per log: 2.85 (2.04 -3.99), P Ͻ 0.001] and NT-proBNP [per log: 1.28 (1.13-1.45), P Ͻ 0.001] predicted death. In the adjusted multivariable model, sST2, but not NTproBNP, was prognostic of mortality [per log: 2.14 (1.37-3.38), P ϭ 0.001]. Decreased eGFR and systolic blood pressure also predicted poor survival (Table 2) .
Of 200 patients with LVEF Ն50%, 196 (98%) completed 1-year follow-up; 20 (10%) of those died. Survival decreased with each tertile of sST2 (first, 96%; second, 95%; third, 79%; log-rank P ϭ 0.001) and NTproBNP (first, 97%; second, 92%; third, 79%; log-rank P ϭ 0.003) (Fig. 2) . Consistent with the data for the full cohort, both sST2 [HR (95%CI) per log: 3.56 (2.21-5.85), P Ͻ 0.001] and NT-proBNP [per log: 1.42 (1.18 -1.71), P Ͻ 0.001] predicted death in an unadjusted analysis, but only sST2 was prognostic after multivariate analysis [per log: 2.57 (1.12-5.91), P ϭ 0.03]. Decreased eGFR and female sex also predicted poor survival after multivariate adjustment (Table 2) .
Of 90 patients with LVEF Ͻ50%, 87 (97%) completed 1-year follow-up; 15 (17%) of those died. Data for patients with LVEF Ͻ50% displayed a pattern of results similar to those with LVEF Ն50%, but HR (95% CI) values for sST2 [per log: 1.74 (0.88 -3.42), P ϭ 0.1] and Kaplan-Meier analysis for tertiles of sST2 (first, 86%; second, 86%; third, 77%; log-rank P ϭ 0.6) did not reach significance because of the small number of events in this subgroup. Table 3 presents clinical variables by tertiles of sST2. Older age, lower eGFR, and greater prevalence of ADHF diagnosis were observed with each increasing tertile of sST2 for all patients and for those with preserved LVEF. Markers of inflammation (hsCRP) and oxidative stress (MPO) also increased with each tertile of sST2.
In a multivariate regression analysis, NT-proBNP (␤ ϭ 0.27, P Ͻ 0.001), cardiac troponin I (␤ ϭ 0.20, P ϭ 0.004), and hsCRP (␤ ϭ 0.25, P Ͻ 0.001) predicted sST2 concentrations. The covariates remained predictive for sST2 even after selecting for those with LVEF Ն50%.
BIOMARKERS AND ECHOCARDIOGRAPHY
As shown in Table 4 , sST2 was significantly associated with echocardiographic measures of ventricular systolic function, mass, cavity size, and diastolic function, but to a lesser extent than NT-proBNP. Although these associations were statistically significant, the explained variance (R 2 ) attributable to sST2 was Ͻ5%. Median sST2 and NT-proBNP concentrations were greater in the 29 patients with E/Em Ͼ15 than the 189 patients with E/Em Յ15 [sST2 median 32.3 U/mL (IQR 24.6 -59.3 U/mL) vs 61.3 U/mL (42.4 -96.7 U/mL), respectively, P ϭ 0.001; NT-proBNP median 127 ng/L (27- When restricting analyses to patients with preserved LVEF, sST2 was not associated with LV mass or (23) 139 (26) 140 (26) 0.9
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81 (15) 78 (15) 80 ( most Doppler measures of diastolic function and had only a weak correlation with E/Em (a semiquantitative surrogate of LV end diastolic pressure). In contrast, NT-proBNP remained correlated with LV mass index, deceleration time, and tissue Doppler measured velocity of the mitral valve annulus. Using the Doppler measure of E/Em Ͼ15 as a surrogate for increased LV end diastolic pressure, we evaluated median sST2 and NTproBNP concentrations in those patients with preserved LVEF and E/Em Ͼ15 (8 individuals). The median sST2 concentration was 58.7 (IQR 50.1-144.4) U/mL, and median NT-proBNP concentration was 9434 (IQR 604 -16146) ng/L. In contrast, those patients with E/Em Յ15 had a median sST2 concentration of 29.6 (23.2-50.6) U/mL and a median NTproBNP concentration of 60 (20 -371) ng/L. P values for the comparison of sST2 and NT-proBNP concentrations between the 2 groups were 0.002 and Ͻ0.001, respectively.
Discussion
Determining the prognosis of patients with acute dyspnea and preserved LVEF can be challenging. When evaluated together, we identified that increased sST2, but not NT-proBNP, was a powerful independent prognosticator of intermediate-term mortality in this population. Furthermore, we identified that although sST2 concentrations were correlated with clinical findings of HF in subjects with and without preserved LVEF, sST2 concentrations, unlike those of NTproBNP, correlated weakly or not at all with echocardiographic parameters of systolic and diastolic dysfunction. These findings suggest that the mechanisms resulting in increased sST2 concentrations are in part pathophysiologically distinct from both natriuretic peptide release and imaging evidence of increased left ventricular filling pressure. This study adds to evidence of sST2 as a powerful predictor of death and further defines the relationship of sST2 with structural heart disease. In previous studies, sST2 has been shown to predict mortality, both alone and in combination with natriuretic peptides, for patients with acute dyspnea or chronic heart failure and after myocardial infarction (5, 6, 8 ) . These data confirm and support the findings of Januzzi et al. (8 ) from the Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department (PRIDE) study, in which sST2 independently predicted death in patients who presented to the ED with acute dyspnea. We extend this earlier finding in 2 important ways: first, in showing that sST2 is strong prognostic marker, above and beyond natriuretic peptides, for patients with dyspnea and preserved LVEF; and second, by evaluating the prognostic value of sST2 in a population comprising a majority of African Americans, a demographic group that has previously been studied only minimally with this biomarker.
These data also provide a comparative analysis that contrasts the associations of NT-proBNP and sST2 with echocardiographic measures. Although NTproBNP was strongly associated with parameters of To put this in perspective, we found an approximately 2-fold higher median sST2 concentration in those with E/Em ratio Ͼ15 (suggestive of increased LV end diastolic filling pressure) than in those without. In contrast, the median NT-proBNP was approximately 157-fold higher in those with E/Em ratio Ͼ15 than in those without. These findings are consistent with a prior study which demonstrated that production sST2 is likely extracardiac by showing that there is a large positive gradient in cardiomyopathy patients between arterial and coronary sinus concentrations of NTproBNP (indicative of myocardial production), but no such gradient exists for sST2 (indicative of nonmyocardial production) (22 ) . sST2 blunts the antiproliferative and antifibrotic effects of IL-33 in the myocardium by acting as a decoy receptor. Thus, increased sST2 concentrations may identify individuals with a greater burden of myocardial fibrosis. However, the weak correlation of sST2 with echocardiography in this unselected dyspnea population, compared with NT-proBNP, brings into question the clinical significance of the stretch-mediated pathway of sST2 secretion. Although in vitro studies define a mechanoreceptorrelated secretion of sST2 from myofibroblasts, in vivo increases of sST2 may be predominantly a result of an inflammatory process. Similar to other markers of inflammation (norepinephrine, tumor necrosis factor, hsCRP, IL-6), increased sST2 may signal the severity of cardiomyopathy (23) (24) (25) (26) . Additionally, increased concentrations of circulating sST2 have been observed in an array of conditions including sepsis, autoimmune conditions, pulmonary disease, infection, and trauma (27) (28) (29) (30) . This is particularly relevant in our unselected dyspnea population, where the cause of acute dyspnea is not necessarily ADHF, and sST2 may, in fact, be predicting death from noncardiovascular disease. The significance of noncardiac etiologies of dyspnea cannot be determined conclusively in our study; however, it is notable that patients with higher concentrations of sST2 were more likely to have physical exam and radiographic findings suggestive of ADHF; thus ADHF was likely to be a primary etiology for sST2 elevation, even in the subset of patients with preserved LVEF. Although our data suggest that sST2 concentrations are not associated with echocardiographic correlates of increased left ventricular pressure or mass compared with NT-proBNP concentrations, sST2 remains a more powerful predictor of mortality than other markers of inflammation in this patient cohort (10 ) .
This study has several limitations. The statistical analysis was not determined a priori, and part of the analysis is focused on the subgroups, thereby increasing the risk for type 1 error. The lack of an a priori statistical analysis with statistical power determination may be particularly relevant to the lack of statistical significance we observed for sST2 to predict 1-year mortality in those with depressed LVEF. The echocardiography data, despite being complete in 81% of patients, lacks detailed evaluation of right ventricular morphology or function. Failure to complete echocardiography in all subjects was often the result of research subject noncompliance with a return visit within 96 h, consistent with the transient nature of an urban ED population. Our study population, therefore, may not reflect the characteristics of dyspnea patients in other settings. Delays in echocardiography (up to 96 h) from time of measurement of serum biomarkers may explain the absence of association of sST2 concentration with echocardiography parameters. However, the strong correlation of echocardiographic measures with NT-proBNP concentrations suggests this is more a true lack of association with sST2 concentration rather than a result of temporal discordance between biomarker measures and echocardiography acquisition. Finally, invasive hemodynamic analysis, although scientifically informative, was not feasible in this ambulatory ED population.
In conclusion, increased sST2 concentrations were an independent predictor of intermediate-term mortality in this population, even after adjusting for NTproBNP concentration. Unlike NT-proBNP, sST2 concentrations correlated poorly with echocardiographic parameters of myocardial function. Therefore, sST2 secretion in acute dyspnea patients may be predominantly modulated by mechanisms other than structural heart disease and myocardial stretch. 
